AMANDA CELLES: Open Payments
NPI 1902391170 · COUSHATTA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,210 in 67 payments from 12 companies in 2025. Trend: 2023 $110 · 2024 $448 · 2025 $1,210
Food & beverage: $1,048Education: $161
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $224 |
| Novo Nordisk Inc | 7 | $202 |
| ABBVIE INC. | 17 | $188 |
| Axsome Therapeutics, Inc. | 10 | $162 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Antares Pharma, Inc. | 2 | $51 |
| Ardelyx, Inc. | 2 | $45 |
| PFIZER INC. | 2 | $36 |
| Lilly USA, LLC | 2 | $30 |
Products named: Auvelity, Wegovy, Kerendia, FARXIGA, QULIPTA, AIRSUPRA, TRINTELLIX, UBRELVY.
Industry payments across LA — which companies pay providers there.
